Idiopathic Pulmonary Fibrosis, Hypoxemia
Conditions
Keywords
IPF, Oxymizer, oxygen conserving device, pulmonary disease
Brief summary
Aim of this study is to investigate the effects of an Oxymizer pendant nasal cannula in hypoxemic patients with idiopathic pulmonary fibrosis during walking.
Detailed description
Patients will be recruited during an inpatient pulmonary rehabilitation program. They will perform three shuttle walk tests on three consecutive days (see below). While performing those tests, the patient's prescribed oxygen flow rate is applicated either through the conventional nasal cannula (CNC) or the Oxymizer.On the first day, patients perform an incremental shuttle walk test to determine maximum walking speed using a conventional nasal cannula. On two consecutive days, patients will perform two endurance shuttle walk tests at 85% of the maximum incremental shuttle walk test speed. Supplemental oxygen will be provided via nasal cannula at the prescribed oxygen flow rate. Patients will be randomly assigned to perform one test with the Oxymizer and the other one with a conventional nasal cannula.
Interventions
DEVICEOxymizer® pendant nasal cannula
Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
Supplemental oxygen is provided by a conventional nasal cannula.
Sponsors
Schön Klinik Berchtesgadener Land
Klaus Kenn
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* firmed diagnosis of idiopathic pulmonary fibrosis * indication for supplemental oxygen therapy during exercise * referred to an inpatient rehabilitation program at the Schön Klinik Berchtesgadener Land
Exclusion criteria
* cardiovascular diseases that influence the patient's physical performance * orthopedic comorbidities that prevent the patient from performing an incremental or endurance shuttle walk test * carbon dioxide pressure above 45 mmHg at rest and ambient air
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endurance shuttle walk test distance | at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test | Distance patients walk during an endurance shuttle walk test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| oxygen saturation | at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test | measured by Sentec Digital Monitoring System |
| heart rate | at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test | measured by Sentec Digital Monitoring System |
| breathing frequency | at baseline, at isotime of endurance shuttle walk test and at the end (maximal 20 min) of endurance shuttle walk test | measured by NoxT3 device |
| carbon dioxide pressure | at baseline, at isotime of endurance shuttle walk test and at the end (maximum 20 min) of endurance shuttle walk test | transcutaneously carbon dioxide pressure measured by Sentec Digital Monitoring System |
| time to desaturation | From beginning of endurance shuttle walk test until the oxygen saturation reaches defined thresholds, or ESWT reaches maximum time frame of 20 minutes | time (seconds) is measured until oxygen saturation drops below 90% or 85 % respectively |
Countries
Germany
Outcome results
None listed